Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Louisiana kicks off PSE e-tracking

This article was originally published in The Tan Sheet

Executive Summary

Louisiana implements the National Precursor Log Exchange June 15 to monitor purchases of OTC products containing pseudoephedrine. Industry bears the cost of deploying and supporting NPLEx through the Consumer Healthcare Products Association, which advocates for electronic tracking of methamphetamine precursors over prescription-only status (1"The Tan Sheet" March 29, 2010, In Brief). Louisiana Gov. Bobby Jindal called NPLEx "a critical tool to help crack down on the sale of drugs that are used to produce meth." Kentucky and Illinois also fully implemented NPLEx. Alabama, Florida, Iowa, Kansas, Missouri, South Carolina and Washington State passed legislation to adopt the NPLEx system, but have yet to implement it, according to CHPA. Oklahoma and Arkansas use separate e-tracking systems. Oregon and Mississippi shifted PSE products to Rx-only availability

Related Content

California one step closer to e-tracking
Kansas selects NPLEx to track PSE purchases





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts